TKI-Based Therapy
PreclinicalSmall molecule
Changchun GeneScience Pharmaceutical Co., Ltd.TKI-Based Therapy is one of 11 small molecule programs targeting Cachexia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Cachexia
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Approved
Beyfortus
BeiGenePhase 2
Actos
TakedaPhase 2
Nanocrystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Megace
Bristol-Myers SquibbPreclinical
Genotropin
Eli LillyPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
AV-380
AAVEO Pharmaceuticals, Inc.
Phase 1
TKI-Based Therapy
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cachexia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TKI-Based Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details